Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
  • C07D471/14—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
  • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
  • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

• ATX also known as ectonucleotide pyrophosphatase/phosphodiesterase family member 2 or ENNP2
• ENNP2 ectonucleotide pyrophosphatase/phosphodiesterase family member 2
• LP A lysophospatidic acid
• the autotaxin-lysophosphatidic acid signaling pathway has been implicated in a variety of signaling pathways involved in cell migration, proliferation, and survival. Due to its role in these pathways, autotaxin has been explored in the last decade as a drug discovery target for the treatment of chronic inflammation, neuropathic pain, fibrotic disease, and various cancers. Intensive efforts have focused on identifying autotaxin inhibitors in the treatment of these disorders.
• kits for reducing blood glucose levels of a subject comprising administering to the subject an autotaxin inhibitor; and thereby decreasing the blood glucose levels of the subject.
• the subject has an elevated blood glucose level.
• the methods comprise measuring the blood glucose level of the subject. In certain embodiments, the methods comprise selecting a subject having an elevated blood glucose level.
• the blood glucose level is a fasted blood glucose level. In certain embodiments, the blood glucose level is a post-prandial blood glucose level. In certain embodiments, the blood glucose level is a whole blood glucose level. In certain embodiments, the blood glucose level is a plasma blood glucose level.
• the blood glucose level is reduced to below 200 mg/dL. In certain embodiments, the blood glucose level is reduced to below 175 mg/dL. In certain embodiments, the blood glucose level is reduced to below 150 mg/dL. In certain embodiments, the blood glucose level is reduced to below 125 mg/dL. In certain embodiments, the blood glucose level is reduced to below 120 mg/dL. In certain embodiments, the blood glucose level is reduced to below 115 mg/dL. In certain embodiments, the blood glucose level is reduced to below 110 mg/dL. In certain embodiments, the blood glucose level is reduced to below 105 mg/dL. In certain embodiments, the blood glucose level is reduced to below 100 mg/dL.
• kits for reducing plasma lysophosphatidic acid levels of a subject comprising administering to the subject an autotaxin inhibitor; and thereby decreasing plasma lysophosphatidic acid levels of a subject.
• the subject has an elevated blood glucose level.
• the subject is insulin resistant.
• kits for improving insulin sensitivity in a subject comprising administering to the subject an autotaxin inhibitor; and thereby improving insulin resistance in the subject.
• kits for preventing or delaying the onset of insulin resistance in a subject at risk for developing insulin resistance comprising administering to the subject an autotaxin inhibitor; and thereby preventing or delaying the onset of insulin resistance in the subject.
• the methods comprise selecting a subject at risk for developing insulin resistance.
• kits for increasing insulin secretion in a subject comprising administering to the subject an autotaxin inhibitor; and thereby increasing insulin secretion in the subject.
• the subject has an elevated blood glucose level.
• kits for improving glucose tolerance in a subject comprising administering to the subject an autotaxin inhibitor; and thereby improving glucose tolerance.
• kits for decreasing adipose tissue expansion in a subject comprising administering to the subject an autotaxin inhibitor; and thereby decreasing adipose tissue expansion in the subject.
• the subject has an elevated blood glucose level.
• the subject is insulin resistant.
• the subject optionally has a metabolic disorder.
• the metabolic disorder is treated by reducing blood glucose levels. In some embodiments, the metabolic disorder is treated by reducing plasma lysophosphatidic acid levels. In some embodiments, the metabolic disorder is treated by improving insulin sensitivity. In some embodiments, the metabolic disorder is treated by increasing insulin secretion. In some embodiments, the metabolic disorder is treated by improving glucose tolerance. In some embodiments, the metabolic disorder is treated by decreasing adipose tissue expansion. In some embodiments, the metabolic disorder does not induce hypoglycemia. [0016] Provided herein are methods for preventing or delaying the onset of at least one metabolic disorder in a subject at risk for developing a metabolic disorder, comprising administering to the subject an autotaxin inhibitor.
• the metabolic disorder is selected from the group consisting of: metabolic syndrome, elevated blood glucose levels, insulin resistance, glucose intolerance, type 2 diabetes, type 1 diabetes, pre-diabetes, non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and obesity.
• metabolic syndrome elevated blood glucose levels, insulin resistance, glucose intolerance, type 2 diabetes, type 1 diabetes, pre-diabetes, non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and obesity.
• the autotaxin inhibitor is administered with at least one additional therapy.
• the at least one additional therapy is a glucose-lowering agent.
• the glucose-lowering agent is selected from among a peroxisome proliferator activated receptor (PPAR) agonist (gamma, dual, or pan), a dipeptidyl peptidase (IV) inhibitor, a glucagon- like peptide- 1 (GLP-I) analog, insulin or an insulin analog, an insulin secretagogue, a sodium glucose co-transporter 2 (SGLT2) inhibitor, a glucophage, a human amylin analog, a biguanide, an alpha-glucosidase inhibitor, a meglitinide, a thiazolidinedione, and sulfonylurea.
• PPAR peroxisome proliferator activated receptor
• IV dipeptidyl peptidase
• GLP-I glucagon- like peptide- 1
• SGLT2 sodium glucose co-
• the at least one additional therapy is metformin, sitagliptin, saxaglitpin, repaglinide, nateglinide, exenatide, liraglutide, insulin lispro, insulin aspart, insulin glargine, insulin detemir, insulin isophane, and glucagon-like peptide 1 , or any combination thereof.
• the at least one additional therapy is a lipid-lowering agent.
• the at least one additional therapy is a therapy used to treat cardiovascular disease.
• the therapy used to treat cardiovascular disease is an angiotensin- converting enzyme (ACE ) inhibitor, angiotensin II receptor blocker (ARB), beta-blocker, diuretic, calcium channel blocker, inhibitor of renin-angiotensin system (RAS), blood-thinning medication, a statin, and a fibrate, and any combination thereof.
• ACE angiotensin- converting enzyme
• ARB angiotensin II receptor blocker
• beta-blocker beta-blocker
• diuretic calcium channel blocker
• calcium channel blocker inhibitor of renin-angiotensin system
• RAS renin-angiotensin system
• blood-thinning medication a statin, and a fibrate, and any combination thereof.
• the at least one additional therapy is administered at the same time as the autotaxin inhibitor.
• the at least one additional therapy is administered less frequently than the autotaxin inhibitor.
• the at least one additional therapy is administered more frequently than the autotaxin inhibitor.
• Figure 2 illustrates the effects of autotaxin inhibitors (Compound A and Compound D) on fasting blood glucose levels in mice fed a high fat diet (HFD).
• Baseline fasting blood glucose top graph
• vehicle vehicle
• Compound A (30 mg/kg)
• Compound D (30 mg/kg) twice daily for two days prior to sampling and once on the day of sampling.
• Total blood glucose AUC bottom graph from these same mice after an i.p. challenge with lg/kg glucose. * p ⁇ 0.02 using t-test.
• Figure 3 illustrates the effects of autotaxin inhibitors (Compound B and Compound E) on fasting blood glucose levels in mice fed a high fat diet (HFD). Baseline fasting blood glucose from normal diet mice and high fat diet mice dosed orally with vehicle (veh), Compound B (30 mg/kg) or Compound E (30 mg/kg) once daily for 5 days prior to sampling. * p ⁇ 0.02 using t-test.
• HFD high fat diet
• a "metabolic disorder” refers to any pathological condition resulting from an alteration in a subject's metabolism. Such disorders include those resulting from an alteration in glucose homeostasis and/or insulin dysfunction. Metabolic disorders, include but are not limited to, metabolic syndrome, elevated blood glucose levels, insulin resistance, glucose intolerance, type 2 diabetes, type 1 diabetes, pre-diabetes, non-alcoholic fatty liver disease, nonalcoholic
• Metabolic disorders are inter-related and can result in disorders across various systems.
• cardiovascular disorders including, e.g., ischemic heart disease, angina and myocardial infarction, congestive heart failure, high blood pressure, abnormal cholesterol levels, deep vein thrombosis, and pulmonary embolism
• neurological disorders including, e.g., stroke, meralgia paresthetica, migraines, idiopathic, and intracranial hypertension, depression and social stigmatism
• rheumatological and orthopedic disorders including, e.g., gout, poor mobility, osteoarthritis, and lower back pain
• dermatological disorders including, e.g., stretch marks, acanthosis nigricans, lymphedema, cellulitis
• gastrointestinal disorders including, e.g., gastroesophageal reflux disease (GERD) and cholelithiasis (gallstones)
• respiratory disorders including, e.g., ischemic heart disease, angina and myocardial infarction, congestive heart failure, high blood pressure, abnormal cholesterol levels
• obstructive sleep apnea including, e.g., obstructive sleep apnea, obesity hypoventilation syndrome, asthma, and increased complications during general anaesthesia
• urology and nephrology disorders including, e.g., obstructive sleep apnea, obesity hypoventilation syndrome, asthma, and increased complications during general anaesthesia
• administering an autotaxin inhibitor to an individual with a metabolic disorder has a variety of desirable outcomes which include, but are not limited to, reducing blood glucose levels, decreasing plasma lysophosphatidic acid levels, improving insulin sensitivity, increasing insulin secretion, improving glucose tolerance, and decreasing adipose tissue expansion. Any of these outcomes can treat, delay or prevent the onset of a metabolic disorder, wherein such metabolic disorders include, but are not limited to, metabolic syndrome, elevated blood glucose levels, insulin resistance, glucose intolerance, type 2 diabetes, type 1 diabetes, pre-diabetes, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and obesity.
• an autotaxin inhibitor reduced fasting blood glucose levels in a mouse fed a high fat diet.
• a mouse fed a high fat diet as illustrated herein, has higher fasting blood glucose levels than a mouse fed a normal diet.
• the administration of an autotaxin inhibitor to a mouse fed a high fat diet reduced fasting blood glucose levels thereby allowing fasting blood glucose levels to approach those levels observed in a mouse fed a normal diet.
• methods disclosed herein comprise administering an autotaxin inhibitor to a subject with elevated blood glucose levels.
• the autotaxin inhibitor is used to treat an underlying metabolic disorder.
• the metabolic disorder is treated by reducing blood glucose levels.
• the subject is overweight or obese.
• the subject has type 2 diabetes.
• the subject has non-alcoholic fatty liver disease and/or nonalcoholic
• the subject does not have a metabolic disorder.
• the autotaxin inhibitor delays or prevents the onset of the metabolic disorder by reducing elevated blood glucose levels.
• the plasma lysophosphatidic acid levels in the individual are elevated relative to a control.
• the control is a person without a metabolic disorder.
• the elevated plasma lysophosphatidic acid levels in the individual contribute to or increase the risk for developing a metabolic disoder.
• Autotaxin (ATX, NPP2, or E-NPP2), an approximately 120 kDa glycoprotein, is a secreted nucleotide pyrophosphatase/phosphodiesterase with lysophospholipase D activity that converts extracellular lysophosphatidylcholine and other lysophospholipids to lysophosphatidic acid. Autotaxin is considered to be responsible for the majority of circulating lysophosphatidic acid (LP A) production.
• LP A circulating lysophosphatidic acid
• Lysophosphatidic acid acts through sets of specific G protein-coupled receptors (GPCRs), such as LPA1, LPA2, LP A3, LPA4, LPA5, LPA6, LPA7, LPA8, in an autocrine and paracrine fashion to produce a variety of biological responses.
• GPCRs G protein-coupled receptors
• Ki 16425 to mice fed a high fat diet improves insulin sensitivity, increases liver glycogen storage, and increases the capacity of a muscle to oxidize glucose, and improves fasting insulin levels.
• the methods disclosed herein comprise administering an autotaxin inhibitor to a subject with elevated plasma lysophosphatidic acid levels relative to a control.
• the control is a person without a metabolic disorder.
• the autotaxin inhibitor is used to treat an underlying metabolic disorder.
• the metabolic disorder is treated by reducing plasma lysophosphatidic acid levels.
• the subject has decreased insulin sensitivity.
• insulin sensitivity in the subject is improved by decreasing plasma lysophosphatidic acid levels.
• the subject has elevated blood glucose levels.
• the elevated blood glucose levels are reduced by reducing lysophosphatidic acid levels.
• the subject does not have a metabolic disorder.
• the autotaxin inhibitor delays or prevents the onset of the metabolic disorder by reducing plasma lysophosphatidic acid levels.
• a subject having elevated blood glucose levels is insulin resistant.
• One of the main functions of insulin is to lower blood glucose levels.
• a subject whose cells are sensitive to the effects of insulin needs only a relatively small amount of insulin to keep blood glucose levels in the normal range.
• a subject who is insulin resistant requires more insulin to get the same blood glucose-lowering effects.
• Insulin resistance may cause hyperinsulinemia. Hyperinsulinemia may be associated with high blood pressure, heart disease and heart failure, obesity (particularly abdominal obesity), osteoporosis, and certain types of cancer, such as colon, breast, and prostate cancer.
• Insulin resistance may be detected using a procedure known as the hyperinsulinemic euglycemic clamp, which measures the amount of glucose necessary to compensate for an increased insulin level without causing hypoglycemia.
• the hyperinsulinemic euglycemic clamp measures the amount of glucose necessary to compensate for an increased insulin level without causing hypoglycemia.
• insulin is infused at 10-120 mU per m2 per minute.
• a 20% solution of glucose is infused to maintain blood sugar levels between 5 and 5.5 mmol/L.
• the rate of glucose infusion is determined by checking the blood sugar levels every 5 to 10 minutes. Low-dose insulin infusions are more useful for assessing the response of the liver, whereas high-dose insulin infusions are useful for assessing peripheral (i.e., muscle and fat) insulin action.
• the rate of glucose infusion during the last 30 minutes of the test determines insulin sensitivity. If high levels (7.5 mg/min or higher) are required, the subject is insulin-sensitive. Very low levels (4.0 mg/min or lower) indicate that the subject is resistant to insulin action. Levels between 4.0 and 7.5 mg/min are not definitive and suggest impaired glucose tolerance. Impaired glucose tolerance may be an early sign of insulin resistance.
• Glucose tracers such as 3-3H glucose, 6,62H-glucose, or 1-13C glucose, may be used in the procedure. Other radioactive forms of glucose may be employed in a research setting. Prior to beginning the hyperinsulinemic period, a 3 hour tracer infusion enables the determination of the basal rate of glucose production. During the clamp procedure, the plasma tracer concentrations enable the calculation of whole-body insulin- stimulated glucose metabolism, as well as the production of glucose by the body (i.e., endogenous glucose production).
• the methods disclosed herein comprise administering an autotaxin inhibitor to a subject with insulin resistance.
• the autotaxin inhibitor improves insulin sensitivity.
• the autotaxin inhibitor treats a metabolic disorder.
• the autotaxin inhibitor treats a metabolic disorder by improving insulin sensitivity.
• the subject does not have a metabolic disorder.
• the autotaxin inhibitor delays or prevents the onset of the metabolic disorder by improving insulin sensitivity.
• mice fed a normal diet and in mice fed a high fat diet injection of exogenous lysophosphatidic acid impairs glucose-induced insulin secretion.
• the autotaxin inhibitor improves insulin secretion by decreasing the level of lysophosphatidic acid.
• a metabolic disorder is treated by increasing insulin secretion.
• the subject does not have a metabolic disorder.
• the autotaxin inhibitor delays or prevents the onset of the metabolic disorder by increasing insulin secretion.
• mice fed a normal diet and in mice fed a high fat diet injection of exogenous lysophosphatidic acid impairs glucose tolerance.
• injection of the inhibitor of lysophosphatidic acid, ⁇ 16425 does not significantly improve glucose tolerance in mice fed a normal diet, but does significantly improve glucose tolerance in mice fed a high fat diet.
• transgenic mouse studies in which autotaxin is selectively deleted from adipocyte tissue improves glucose intolerance and insulin resistance induced by a high fat diet.
• described herein is a method of improving glucose tolerance in an individual comprising administering an autotaxin inhibitor to the subject with impaired glucose tolerance.
• the autotaxin inhibitor improves glucose tolerance in the individual by decreasing the plasma level of lysophosphatidic acid.
• the individual has a metabolic disorder and the metabolic disorder is treated by improving glucose tolerance.
• the subject does not have a metabolic disorder.
• the autotaxin inhibitor delays or prevents the onset of a metabolic disorder in an individual by improving glucose tolerance.
• described herein is a method for decreasing adipose tissue expansion in a subject comprising administering to the subject an autotaxin inhibitor.
• control mice homozygous autotaxin mice
• a high fat diet have higher weight gains than the heterozygous deficient transgenic mice, despite no change in food intake.
• the autotaxin deficiency in the transgenic mice similarly suppress adipose mass expansion, improved metabolism, and had less inflammation when compared to control mice also fed a high fat diet.
• described herein is a method of treatment of a metabolic disorder in a subject that is overweight or obese.
• an autotaxin inhibitor is used to treat obesity in a subject.
• the autotaxin inhibitor decreases adipose tissue expansion in the subject that is overweight or obese.
• the metabolic disorder is treated by decreasing adipose tissue expansion.
• administering delays or prevents the onset of a metabolic disorder by decreasing adipose tissue expansion.
• the subject is at risk for developing a metabolic disorder.
• administration of an autotaxin inhibitor to a subject treats, prevents, or ameliorates the symptoms of drug induced hyperglycemia.
• administration of an autotaxin inhibitor to a subject treats, prevents, or ameliorates the symptoms of drug induced hyperglycemia by reducing blood glucose levels.
• Pharmacological agents can affect glucose homestasis that can result in hyperglycemia.
• the hyperglycemia occurs in the absence of a diagnosis of diabetes. If left untreated, the elevated blood glucose levels can lead to a medical emergency. Symptoms include, but are not limited to fatigue, weakness, fruity odor of the breath, confusion, lack of concentration, shortness of breath, nausea, vomiting, dry skin, and flushing of the skin.
• antibiotics such as fluoroquinolones including gatifloxacin
• beta-blockers such as propranolol,metoprolol or atenolol
• thiazide such as hydrochlorothiazide, and thiazide-like diuretics, and thiazide-like drugs (metolazone)
• SGAs second-generation antipsychotics
• "atypical antipsychotics” such as olanzapine or clozapine
• corticosteroids calcinuerin inhibitors such as cyclosporine,sirolimus or tarcrolimus
• protease inhibitors such as ritonavir.
• administration of an autotaxin inhibitor to a subject treats or prevents or delays the onset of stress induced hyperglycemia. In some embodiments,
• SIH Stressed induced hyperglycemia
• a subject treats or prevents or delays the onset of stress induced hyperglycemia by reducing blood glucose levels.
• Stressed induced hyperglycemia is a transient increase in plasma glucose levels higher than 200 mg/dL which occurs during an acute illness or injury. In some embodiments, the hyperglycemia occurs in the absence of a diagnosis of diabetes. The SIH results from an excess of glucose production relative glucose clearance. SIH has been associated with conditions including, but not limited to, myocardial infarction, stroke, and trauma. SIH has been associated with increase mortality and a higher incidence of congestive heart failure and cardiogenic shock in patients after myocardial infarction.
• the methods provided herein comprise measuring blood glucose levels.
• Blood glucose levels may be measured before and/or after administration of an autotaxin inhibitor.
• Blood glucose levels may be measured in whole blood, or may be measured in plasma.
• Blood glucose levels may be measured in a clinical laboratory, or may be measured using a blood glucose meter.
• blood glucose levels are measured in a subject when the subject has fasted for at least 8 hours. In certain embodiments, blood glucose levels are measured at random times, and the measurement is not timed according to the intake of food or drink. In certain embodiments, blood glucose levels are measured in the post-prandial state, i.e. after the subject has eaten a meal. In certain embodiments, blood glucose levels are measured in a subject two hours after the subject has eaten a meal. In certain embodiments, blood glucose levels are measured at timed intervals following administration of glucose to the subject, in order to determine how quickly the subject's body clears glucose from the blood. Any measurements of blood glucose levels may be made in whole blood or in plasma.
• the subject has elevated blood glucose levels.
• a subject is identified as having elevated blood glucose levels. Such identification is typically made by a medical professional.
• an elevated blood glucose level is a fasting blood glucose level between 100 and 125 mg/dL.
• an elevated blood glucose level is a fasting blood glucose level above 126 mg/dL.
• an elevated blood glucose level is a two-hour post-prandial glucose level between 140 and 199 mg/dL.
• an elevated blood glucose level is a two-hour postprandial glucose level at 200 mg/dL or higher.
• a subject having elevated blood glucose levels has pre-diabetes.
• a subject is identified as having pre-diabetes. In certain such
• the subject has a fasting blood glucose level between 100 and 125 mg/dL. In certain such embodiments, the subject has a two-hour post-prandial blood glucose level between 140 and 199 mg/dL.
• a diagnosis of pre-diabetes is typically made by a medical professional, who may consider factors in addition to blood glucose levels when determining whether a subject has pre-diabetes.
• a subject having elevated blood glucose levels has diabetes.
• a subject is identified as having diabetes according to the subject's blood glucose levels.
• the subject has a fasting blood glucose level above 126 mg/dL.
• the subject has a two-hour post-prandial blood glucose level at or above 200 mg/dL.
• a diagnosis of diabetes is typically made by a medical professional, who may consider factors in addition to blood glucose levels when determining whether a subject has diabetes.
• the methods provided herein comprise monitoring blood glucose levels before administration of an autotaxin inhibitor. In certain embodiments, the methods provided herein comprise measuring blood glucose levels after administration of an autotaxin inhibitor. In certain embodiments, a subject measures blood glucose levels one or more times daily.
• methods for reducing blood glucose levels comprise reducing a subject's blood glucose levels to blood glucose levels determined as desirable by medical organizations, such as the American Diabetes Association or the World Health Organization.
• blood glucose levels are reduced below 130 mg/dL when measured before a subject has had a meal.
• blood glucose levels are reduced to below 180 mg/dL when measured after a subject has had a meal.
• HbAlc levels may be used to determine how well a subject's blood glucose levels are controlled over time.
• HbAlc levels are an indication of the amount of glycated hemoglobin in the blood, and can provide an estimate of how well a subject's blood glucose levels have been managed over 2-3 month period prior to the measurement of HbAlc levels.
• High HbAlc levels may put a subject at risk for developing complications related to diabetes, such as eye disease, heart disease, kidney disease, nerve damage, or stroke.
• an HbAlc level of 6% or less is normal.
• a medical professional may recommend that a subject's HbAlc level be 7% or less.
• the administering results in reduced HbAlc levels.
• a control is the blood glucose levels of an individual without a metabolic disorder.
• a control is a blood glucose level lower than 100 mg/dL.
• the autotaxin inhibitor is used to treat an underlying metabolic disorder.
• the metabolic disorder is treated by reducing blood glucose levels by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 45%, and 50%.
• the blood glucose level is reduced to below 200 mg/dL.
• the blood glucose level is reduced to below 175 mg/dL.
• the blood glucose level is reduced to below 150 mg/dL.
• the blood glucose level is reduced to below 125 mg/dL.
• the blood glucose level is reduced to below 120 mg/dL. In certain embodiments, the blood glucose level is reduced to below 115 mg/dL. In certain embodiments, the blood glucose level is reduced to below 110 mg/dL. In certain embodiments, the blood glucose level is reduced to below 105 mg/dL. In certain embodiments, the blood glucose level is reduced to below 100 mg/dL.
• the subject is overweight or obese. In some embodiments, the subject has type 2 diabetes. In some embodiments, the subject has metabolic syndrome. In some embodiments, the subject has non-alcoholic fatty liver disease and/or nonalcoholic
• the subject does not have a metabolic disorder.
• the autotaxin inhibitor delays or prevents the onset of the metabolic disorder by reducing elevated blood glucose levels relative to a control.
• a control is a blood glucose level lower than 110 mg/dL.
• the elevated blood glucose levels are reduced by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%), 35%), 45%), and 50%>.
• the blood glucose level is reduced to below 200 mg/dL. In certain embodiments, the blood glucose level is reduced to below 175 mg/dL. In certain embodiments, the blood glucose level is reduced to below 150 mg/dL. In certain embodiments, the blood glucose level is reduced to below 125 mg/dL. In certain embodiments, the blood glucose level is reduced to below 120 mg/dL. In certain embodiments, the blood glucose level is reduced to below 115 mg/dL. In certain embodiments, the blood glucose level is reduced to below 110 mg/dL. In certain embodiments, the blood glucose level is reduced to below 105 mg/dL. In certain embodiments, the blood glucose level is reduced to below 100 mg/dL.
• the plasma lysophosphatidic acid levels in the individual are elevated relative to a control.
• the plasma lysophosphatidic acid levels of the control are at least 1.2 mM or lower.
• the control is the lysophosphatidic acid levels of an individual without a metabolic disorder.
• the elevated plasma lysophosphatidic acid concentrations in the individual contribute to or increase the risk for developing a metabolic disorder.
• the methods disclosed herein comprise administering an autotaxin inhibitor to an individual with elevated lysophosphatidic acid levels to treat an underlying metabolic disorder.
• the metabolic disorder is treated by reducing plasma lysophosphatidic acid levels with an autotaxin inhibitor.
• the lysophosphatidic acid levels are reduced by the autotaxin inhibitor by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 45%, and 50%.
• the subject has decreased insulin sensitivity. In some embodiments, insulin sensitivity in the subject is improved by decreasing plasma lysophosphatidic acid levels. In some embodiments, the subject has elevated blood glucose levels relative to a control. In some embodiments, a control is the blood glucose levels of an individual without a metabolic disorder. In some embodiments, the elevated blood glucose levels are reduced by reducing lysophosphatidic acid levels.
• the subject does not have a metabolic disorder.
• the autotaxin inhibitor delays or prevents the onset of the metabolic disorder by reducing plasma lysophosphatidic acid levels by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 45%, and 50%.
• the subject has insulin resistance.
• the individual with insulin resistance has fasting insulin levels of at least 20 ⁇ /mL. In some embodiments, the individual with insulin resistance has fasting insulin levels that exceed 100 ⁇ /mL.
• the autotaxin inhibitor treats a metabolic disorder by improving insulin resistance. In some embodiments, the autotaxin inhibitor treats a metabolic disorder by improving insulin sensitivity. In certain embodiments, the methods comprise selecting a subject having insulin resistance.
• kits for preventing or delaying the onset of insulin resistance in a subject at risk for developing insulin resistance comprising administering to the subject an autotaxin inhibitor; and thereby preventing or delaying the onset of insulin resistance in the subject.
• the methods comprise selecting a subject at risk for developing insulin resistance.
• the autotaxin inhibitor improves insulin secretion by decreasing the level of lysophosphatidic acid.
• a metabolic disorder is treated by increasing insulin secretion.
• the subject does not have a metabolic disorder.
• the autotaxin inhibitor delays or prevents the onset of the metabolic disorder by increasing insulin secretion.
• described herein is a method of improving glucose tolerance in an individual comprising administering an autotaxin inhibitor to the subject with impaired glucose tolerance.
• the autotaxin inhibitor improves glucose tolerance in the individual by decreasing the level of lysophosphatidic acid.
• the individual has a metabolic disorder and the metabolic disorder is treated by improving glucose tolerance.
• the subject does not have a metabolic disorder.
• the autotaxin inhibitor delays or prevents the onset of a metabolic disorder in an individual by improving glucose tolerance.
• described herein is a method for decreasing adipose tissue expansion in a subject comprising administering to the subject an autotaxin inhibitor.
• described herein is a method of treatment a metabolic disorder in a subject that is overweight or obese.
• an autotaxin inhibitor is used to treat obesity in a subject.
• the autotaxin inhibitor decreases adipose tissue expansion in the subject that is overweight or obese.
• the metabolic disorder is treated by decreasing adipose tissue expansion.
• administration of an autotaxin inhibitor to a subject delays or prevents the onset of a metabolic disorder by decreasing adipose tissue expansion.
• the subject is at risk for developing a metabolic disorder.
• Blood glucose level means the concentration of glucose in the blood of a subject.
• blood glucose levels are expressed as milligrams of glucose per deciliter of blood.
• blood glucose levels are expressed as mmol of glucose per liter of blood.
• Elevated blood glucose level means a blood glucose level that is higher than normal.
• “Fasted blood glucose level” means a blood glucose level after a subject has fasted for a certain length of time. For example, a subject may fast for at least 8 hours prior to measurement of a fasted blood glucose level.
• Post-prandial blood glucose level means a blood glucose level after a subject has eaten a meal. In certain embodiments, a post-prandial blood glucose level is measured two hours after a subject has eaten a meal.
• Plasma blood glucose level means the concentration of glucose in plasma following separation of whole blood into plasma and red blood cell fractions.
• Plasma lysophosphatidic acid level means the concentration of lysophosphatidic acid in plasma following separation of whole blood into plasma and red blood cell fractions.
• Impaired glucose intolerance is defined as a two-hour glucose levels (glycemia) of about 140 to about 199 mg/dL (7.8 to 11.0 mmol) on the 75-g oral glucose tolerance test
• Insulin sensitivity means the ability of cells to take up glucose in response to insulin action.
• Insulin resistance means a condition in which normal amounts of insulin are inadequate to produce a normal insulin response from fat, muscle and liver cells. Insulin resistance in fat cells results in hydrolysis of stored triglycerides, which elevates free fatty acids in the blood. Insulin resistance in muscle reduces the uptake of glucose from the blood by muscle cells. Insulin resistance in liver reduces glucose storage and a failure to suppress glucose production. Elevated free fatty acids, reduced glucose uptake, and elevated glucose production all contribute to elevated blood glucose levels. High plasma levels of insulin and glucose due to insulin resistance often leads to metabolic syndrome and type 2 diabetes.
• insulin resistance means increasing the ability of cells to produce a normal insulin response.
• insulin resistance is improved in muscle cells, leading to an increased uptake of glucose in muscle cells.
• insulin resistance is improved in liver cells, leading to increased glucose storage in liver cells.
• insulin resistance is improved in fat cells, leading to reduced hydrolysis of triglycerides, and consequently reduced free fatty acid in the blood.
• Adipose tissue expansion means an increase in the size of adipose cells compared to the normal size of adipose cells. In certain embodiments, the adipose tissue expansion is due to a high fat diet consumed by the subject. [0077] “Hypoglycemia” refers to a condition in which the blood glucose level is too low.
• hypoglycemia occurs when the blood glucose level falls below 70 mg/dl in an individual.
• Prediabetes means a condition in which a subject's blood glucose levels are higher than in a subject with normal blood glucose levels but lower but not high enough for a diagnosis of diabetes.
• AIC levels are at least 6.0% or greater.
• fasting plasma glucose levels are at least 5.6 mmol/L (100 mg/dL) or greater.
• Type 1 diabetes means diabetes characterized by loss of the insulin-producing beta cells of the islets of Langerhans in the pancreas leading to a deficiency of insulin (also known as insulin-dependent diabetes mellitus or IDDM). Type I diabetes can affect children or adults, but typically appears between the ages of 10 and 16.
• Type 2 diabetes means diabetes characterized by insulin resistance and relative insulin deficiency (also known as diabetes mellitus type 2, and formerly called diabetes mellitus type 2, non-insulin-dependent diabetes (NIDDM), obesity related diabetes, or adult-onset diabetes).
• NIDDM non-insulin-dependent diabetes
• Obsity means an excessively high amount of body fat or adipose tissue in relation to lean body mass.
• the amount of body fat (or adiposity) includes both the distribution of fat throughout the body and the size of the adipose tissue deposits.
• Body fat distribution can be estimated by skin-fold measures, waist-to-hip circumference ratios, or techniques such as ultrasound, computed tomography, or magnetic resonance imaging. According to the Center for Disease Control and Prevention, individuals with a body mass index (BMI) of 30 or more are considered obese.
• BMI body mass index
• Metabolic syndrome means a condition characterized by a clustering of lipid and nonlipid risk factors of metabolic origin.
• metabolic syndrome is identified by the presence of any 3 of the following factors: waist circumference of greater than 102 cm in men or greater than 88 cm in women; serum triglyceride of at least 150 mg/dL; HDL- C less than 40 mg/dL in men or less than 50 mg/dL in women; blood pressure of at least 130/85 mmHg; and fasting glucose of at least 110 mg/dL.
• Non-alcoholic fatty liver disease refers to a fatty liver disease that occurs when fat is deposited in the liver not due to excessive alcohol use.
• Nonalcoholic steatohepatitis refers to a liver inflammation caused by a buildup of fat in the liver that is not due to alcohol abuse
• Subject or “individual” means a mammal. In some embodiments, the mammal is a human.
• the terms “administer,” “administering”, “administration,” and the like, as used herein, refer to the methods that may be used to enable delivery of compounds or compositions to the desired site of biological action. These methods include, but are not limited to oral routes of administration, intraduodenal routes of administration, parenteral injection (including
• intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular or infusion), topical and rectal administration Any suitable route of administration of the autotaxin inhibitors described herein is contemplated.
• the compounds and compositions described herein are administered orally.
• At risk for developing means a subject is predisposed to developing a condition or disease.
• a subject at risk for developing a condition or disease exhibits one or more symptoms of the condition or disease, but does not exhibit a sufficient number of symptoms to be diagnosed with the condition or disease.
• a subject at risk for developing a condition or disease exhibits one or more symptoms of the condition or disease, but to a lesser extent required to be diagnosed with the condition or disease.
• treat include alleviating, abating or ameliorating at least one symptom of a disease or condition, preventing additional symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition either prophylactically and/or therapeutically.
• Prevent the onset of means to prevent the development a condition or disease in a subject who is at risk for developing the disease or condition.
• a subject at risk for developing the disease or condition receives treatment similar to the treatment received by a subject who already has the disease or condition.
• Delay the onset of means to delay the development of a condition or disease in a subject who is at risk for developing the disease or condition.
• a subject at risk for developing the disease or condition receives treatment similar to the treatment received by a subject who already has the disease or condition.
• an autotaxin inhibitor contemplated for use in any of the embodiments described herein is: a protein, a peptide, a polypeptide, a peptidomimetic, an antibody, a small molecule, a small interfering R A-encoding polynucleotide, an antisense RNA-encoding polynucleotide, or a ribozyme-encoding polynucleotide.
• the autotaxin inhibitor is an antibody to autotaxin.
• Autotaxin inhibitors contemplated herein interact with autotaxin directly so as to alter the activity of autotaxin, by way of example only, to inhibit the activity of autotaxin, to limit the activity of autotaxin.
• the autotaxin inhibitor contemplated for use in any of the embodiments described herein is a small molecule inhibitor.
• the autotaxin inhibitor is a small molecule inhibitor that is characterized as having one or more of the following properties:
• the autotaxin inhibitor is a small molecule heterocyclic compound. In some embodiments, the autotaxin inhibitor is a small molecule indole derivative. In some embodiments, the autotaxin inhibitor is small molecule tetracyclic compound. In some embodiments, the autotaxin inhibitor is small molecule piperidine or piperazine containing compound. In some embodiments, the autotaxin inhibitor is a small molecule benzonaphtyridine derivative. In some embodiments, the autotaxin inhibitor is a small molecule pyrimidine derivatives. In some embodiments, the autotaxin inhibitors are imidazole derivatives. In some embodiments, the autotaxin inhibitors are bicyclic derivatives.
• the autotaxin inhibitors are diazaspirocycloalkane or azaspirocycloalkane derivatives. In some embodiments, the autotaxin inhibitors are pyridazine derivatives. In some embodiments, the autotaxin inhibitors are pyrimidine and pyridine derivatives. In some embodiments, the autotaxin inhibitors are pipemidic acid derivatives. In some embodiments, the autotaxin inhibitors are thiazole derivatives.
• the autotaxin inhibitor is a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, as described in US Provisional Application No. 61/883,026 (filed on September 26, 2013), US Provisional Application No. 62/038,052 (filed on August 15, 2014), International Patent Application No. PCT/US2014/057477 (filed on September 25, 2014):
• the autotaxin inhibitor is a compound as described in Tables 1-4 of US Provisional Application No. 61/883,026. In other embodiments, the autotaxin inhibitor is a compound having the structure Al, A2, A3, A4, or A5 as described in Paragraph [00244] of US Provisional Application No. 61/883,026. In other embodiments, the autotaxin inhibitor is a compound of any one of Examples 1-79 as described in US Provisional Application No.
• the autotaxin inhibitor is a compound as described in Tables 1-4 of US Provisional Application No. 62/038,052. In other embodiments, the autotaxin inhibitor is a compound having the structure Al, A2, A3, A4, or A5 as described in Paragraph [00246] of US Provisional Application No. 62/038,052. In other embodiments, the autotaxin inhibitor is a compound of any one of Examples 1-121 as described in US Provisional
• the autotaxin inhibitor is a compound as described in Tables 1-5 of International Patent Application No. PCT/US2014/057477.
• the autotaxin inhibitor is a compound having the structure Al, A2, A3, A4, or A5 as described in Paragraph [00266] of International Patent Application No. PCT/US2014/057477.
• the autotaxin inhibitor is a compound of any one of Examples 1-133 as described in International Patent Application No. PCT/US2014/057477.
• the autotaxin inhibitor has the following structure:
• Compound E is used as the sodium salt. [0099] In some embodiments Compound E is used in racemic form. In some embodiments the R-enantiomer of Compound E is used. In some embodiments the S-enantiomer of Compound E is used.
• the autotaxin inhibitor is a compound of Formula (I), or pharmaceutically acceptable salt, pharmaceutically acceptable solvate or prodrug thereof, as described in US Provisional Application No. 61/878,922 (filed on September 17, 2013),
• the autotaxin inhibitor is a compound as described in Table 1 or 2 of US Provisional Application No. 61/878,922. In other embodiments, the autotaxin inhibitor is a compound as described in Table 1 or 2 of International Patent Application No.
• the autotaxin inhibitor is a compound as described in paragraph [[00197] of International Patent Application No. PCT/US2014/055901. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-49 in International Patent Application No. PCT/US2014/055901.
• the autotaxin inhibitor is a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, as described in US Provisional Application No. 61/907,947 (filed on November 22, 2013), US Provisional Application No. 62/038,093 (filed on August 15, 2014), International Patent Application No. PCT/US2014/066705 (filed on November 20, 2014):
• the autotaxin inhibitor is a compound as described in Paragraph [00116], [00117], [00122], [00123], [00125], [00126], [00128], [00129], [00131] or [00132] of US Provisional Application No. 61/907,947, US Provisional Application No. 62/038,093.
• the autotaxin inhibitor is a compound as described in Paragraph [00116], [00135], [00136], [00144], [00145], [00147], [00148], [00150], [00151], [00153]-[00155], or [00174]-[00179] of International Patent Application No. PCT/US2014/066705.
• the autotaxin inhibitor is a compound as described in Table 1, 2, or 3 of US Provisional Application No. 61/907,947. In other embodiments, the autotaxin inhibitor is a compound as described in Table 1, 2, 3, or 4 of US Provisional Application No. 62/038,093. In other embodiments, the autotaxin inhibitor is a compound as described in Table 1, 2, or 3 of International Patent Application No. PCT/US2014/066705. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-13 of US Provisional Application No. 61/907,947. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-53 of US Provisional Application No. 62/038,093. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-51 of International Patent Application No. PCT/US2014/066705.
• the autotaxin inhibitor has the following structure:
• Compound A is used as the sodium salt.
• Compound A is used in racemic form. In some embodiments, the R-enantiomer of Compound A is used. In some embodiments the S-enantiomer of Compound A is used.
• the autotaxin inhibitor is a compound of Formula (I), or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or prodrug thereof, as described in US Provisional Application No. 61/878,945 (filed on September 17, 2013), International Patent Application No. PCT/US2014/055899 (filed on September 16, 2014):
• the autotaxin inhibitor is a compound as described in Table 1, 2, 3, 4, 5, or 6 of US Provisional Application No. 61/878,945, or International Patent Application No. PCT/US2014/055899. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-13 of US Provisional Application No. 61/878,945 or
• the autotaxin inhibitor is a compound of Formula (I), or a pharmaceutically acceptable salt, or solvate thereof as described in US Provisional Application No. 61/907,965 (filed on November 22, 2013), US Provisional Application No. 62/038,121 (filed on August 15, 2014), International Patent Application No. PCT/US2014/066706 (filed on November 20, 2014):
• the autotaxin inhibitor is a compound as described in Paragraph [00135] of US Provisional Application No. 61/907,965, US Provisional Application No.
• the autotaxin inhibitor is a compound as described in Table 1 or Table 2 of International Patent Application No. PCT/US2014/066706. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-8 of US Provisional Application No. 61/907,965. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-10 of US Provisional Application No. 62/038,121. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-29 of International Patent Application No. PCT/US2014/066706. [00111 In some embodiments, the autotaxin inhibitor has one of the following structures:
• Compound B is used as the sodium salt.
• Compound C is used as the sodium salt.
• Compound D is used as the sodium salt.
• the autotaxin inhibitor is a compound of Formula (I), or a pharmaceutically acceptable salt, or pharmaceutically acceptable solvent or prodrug thereof as described in WO 2012/166415 (published on December 6, 2012):
• the autotaxin inhibitor is a compound as described in Table 1 of WO 2012/166415. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-18 of WO 2012/166415.
• the autotaxin inhibitor is a compound of Formula (I), or a pharmaceutically acceptable salt, or pharmaceutically acceptable solvent or prodrug thereof as described in WO 2012/024620 (published on copy 23, 2012):
• the autotaxin inhibitor is a compound as described in Table 1, 2, 3 or 4 of WO 2012/024620. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-157 of WO 2012/024620.
• the autotaxin inhibitor is a compounds of Formula I as described in WO 2009/046841 (published on April 16, 2009):
• the autotaxin inhibitor is a compound described in the table on pages 65-101 in WO 2009/046841. In other embodiments, the autotaxin inhibitor is a compound described in the table on pages 104-106 of WO 2009/046841.
• the autotaxin inhibitor is a compound of Formula I as described in WO 2010/060532 (published on June 3, 2010):
• the autotaxin inhibitor is the compound of Example 1 ("Al") as described in WO 2010/060532. In other embodiments, the autotaxin inhibitors is a compound described on pages 49-108 of WO 2010/060532.
• the autotaxin inhibitor is a compound of Formula I as described in WO 2011/006569 (published on January 20, 2011):
• the autotaxin inhibitor is compound A173 of Example 18 as described in WO 2011/006569. In other embodiments, the autotaxin inhibitor is a compound as described on pages 69-141 of WO 2011/006569. [00123] In some embodiments, the autotaxin inhibitor is a compound of Formula la, lb, and II as described in WO 2010/115491 (published on October 14, 2010):
• the autotaxin inhibitor is Compound las described in WO 2010/115491. In other embodiments, the autotaxin inhibitors are the compounds of Table 2 as described in WO 2010/115491.
• the autotaxin inhibitor is a compound of Formula I as described in WO 2010/063352 (published on June 10, 2010):
• the autotaxin inhibitor is Compound 8 as described in WO 2010/063352.
• the autotaxin inhibitors are the compounds of 1-157 as described in WO 2010/063352.
• the autotaxin inhibitor is a compound as described in Table 2 of WO 2010/063352.
• the autotaxin inhibitor is a compound of Formula I as described in WO 2009/046804 (published on April 16, 2009):
• the autotaxin inhibitor is compound A2 as described in WO 2009/046804. In other embodiments, the autotaxin inhibitor is a compound as described on pages 64-115 of WO 2009/046804.
• the autotaxin inhibitor is a compound of Formula I, or a pharmaceutically acceptable salt thereof, as described in WO 2014/097151 (published on June 26, 2014):
• the autotaxin inhibitor is embodiment 27 (page 37) as described in WO 2014/09151. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-75 of WO 2014/097151.
• the autotaxin inhibitor is a compound of Formula I, or a pharmaceutically acceptable salt thereof, as described in WO 2014/048865 (Published April 3, 2014):
• the autotaxin inhibitor is a compound as described in the tables on pages 85-256 of WO 2014/048865. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-44 of WO 2014/048865.
• the autotaxin inhibitor is a compound of Formula I, or a pharmaceutically acceptable salt thereof, as described in WO 2013/186159 (published on
• the autotaxin inhibitor is a compound as described in Table 1, 2, 3, 4, 5, 6, or 7 of WO 2013/186159. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-16 of WO 2013/186159. In other embodiments, the autotaxin inhibitor is a compound as described in the table on pages 89-95 of WO 2013/186159.
• the autotaxin inhibitor is a compound of Formula I, or a pharmaceutically acceptable salt thereof, as described in WO 2013/061297 (published on May 2, 2013):
• the autotaxin inhibitor is a compound as described in Table 1 of WO 2013/061297. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-14 of WO 2013/061297.
• the autotaxin inhibitor is a compound of Formula I, or a pharmaceutically acceptable salt thereof, as described in WO 2013/054185 (published on April 18, 2013):
• the autotaxin inhibitor is a compound described in Table 1 of WO 2013/054185. In other embodiments, the autotaxin inhibitor is a compound as described in any one of Example Number 1-53 of WO 2013/054185.
• the autotaxin inhibitor is a compound as described in US Patent No. 8,268,891 (issued on September 18, 2012; US Application No 12/270,840). In some embodiments, the autotaxin inhibitor is compound 7905958, 5186522, 7839888, 5761473, 5564949, 5538444, 5711925, 5564676, 7921385, or 5210574 as described in US Patent No. 8,268,891.
• the autotaxin inhibitor is a compound as described in US Patent No. 8,497,371 (issued on July 30, 2013; US Patent Application No 12/912,604). In other embodiments, the autotaxin inhibitor is a compound as described in any one of Examples 1-31 of US Patent No. 8,497,371.
• the autotaxin inhibitor is a compound of Formula Ia-Im as described in WO 2011/044978 (published on April 21, 2011). In other embodiments, the autotaxin inhibitor is a compound described on pages 36-42 of WO 2011/044978. [00142] In some embodiments, the autotaxin inhibitor is a compound of Formula I as described in WO 2010/112116 (published on October 7, 2010):
• the autotaxin inhibitor is a compound as described in any one of Examplesl-11 of WO 2010/112116. In other embodiments, the autotaxin inhibitor is compound described in the table on pages 63-69 of WO 2010/112116.
• the autotaxin inhibitor is a compound of Formula I as described in WO 2009/046842 (published on April 16, 2009):
• the autotaxin inhibitor is a compound as described in any one of the tables on pages 56-72 of WO 2009/046842.
• the autotaxin inhibitor is a boronic acid based compound.
• the autotaxin inhibitors is HA155, HA130, or E-HA219.
• Boronic acid based autotaxin inhibitors include and are not limited to those disclosed in H. M. Albers et al., J. Med. Chem. 2011, 54, 4619-4626; H. M. Albers et al, J. Med. Chem. 2010, 53, 4958-4967; and H. M. Albers et al, Proc. Natl. Acad. Sci. USA 2010, 107, 7257-7262.
• autotaxin inhibitors contemplated for use include but are not limited to PF-8380, vinpocetin, damnacanthal, NSC-48300, NSC-9616, H2L-7905958, bithionol, NSC 12859, NSC 75779, NSC 5014, NSC 341348, NSC 75520, hexachlorophene, merbromin, eosin Y and 2,2'- methylenebis(4-chlorophenol).
• the autotaxin inhibitors are the
• the autotaxin inhibitors are compounds that are lipids or lipid based.
• the autotaxin inhibitor is lysophosphatic acid (LP A).
• the autotaxin inhibitor is sphingosine 1 -phosphate (SIP).
• the autotaxin inhibitors are LP A or SIP analogs.
• the autotaxin inhibitors are phosphates analogs.
• the autotaxin inhibitors are phosphonates analogs.
• the autotaxin inhibitors are thiophosphates.
• the autotaxin inhibitors are phosphosphatidic acids derivatives. In some embodiments, the autotaxin inhibitors are cyclic phosphatidic acid analogs. In some
• the autotaxin inhibitors are tyrosine based.
• Other autotaxin inhibitors contemplated for use include and are not limited to FTY720-
• Additional autotaxin inhibitors contemplated for use include and are not limited to, those described in G. G. Durgam et. al, Bioorg. Med. Chem. Lett. 2006, 16, 633-640; G. G.
• Patent Application No. 12/351,550 US Patent No. 8,378,100 (issued on February 19, 2013; US
• the autotaxin inhibitors are metal chelators.
• the autotaxin inhibitors include, but are not limited to, L-histidine,
• EDTA ethylenediaminetetraacetic acid
• 1,10-phenanthroline 1,10-phenanthroline
• the autotaxin inhibitors include the compounds disclosed in E. Barbayianni et al, Expert Opin Ther Pat. 2013, 23 (9), 1123-1132; A. L. Parrill and D. L. Baker, Expert Opin Ther Pat. 2010, 20(12), 1619-1625; L. Federico et al, Curr Drug Targets 2008, 9(8), 698-708; and H. M. Albers and H. Ovaa, Chem. Rev. 2012, 112, 2593-2603; all of which are incorporated by reference for the disclosure of such compounds.
• Other Forms are also be found in E. Barbayianni et al, Expert Opin Ther Pat. 2013, 23 (9), 1123-1132; A. L. Parrill and D. L. Baker, Expert Opin Ther Pat. 2010, 20(12), 1619-1625; L. Federico et al, Curr Drug Targets 2008, 9(8), 698-708; and H. M. Albers and H. Ovaa, Chem. Rev. 2012, 112, 2593
• compounds described herein are in the form of pharmaceutically acceptable salts.
• active metabolites of these compounds having the same type of activity are included in the scope of the present disclosure.
• the compounds described herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
• the solvated forms of the compounds presented herein are also considered to be disclosed herein.
• “Pharmaceutically acceptable,” as used herein, refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively nontoxic, i.e., the material is administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
• pharmaceutically acceptable salt refers to a form of a therapeutically active agent that consists of a cationic form of the therapeutically active agent in combination with a suitable anion, or in alternative embodiments, an anionic form of the therapeutically active agent in combination with a suitable cation.
• Handbook of Pharmaceutical Salts Properties, Selection and Use. International Union of Pure and Applied Chemistry, Wiley- VCH 2002. S.M. Berge, L.D. Bighley, D.C. Monkhouse, J. Pharm. Sci. 1977, 66, 1-19. P. H. Stahl and C. G. Wermuth, editors, Handbook of Pharmaceutical Salts: Properties, Selection and Use,
• salts typically are more soluble and more rapidly soluble in stomach and intestinal juices than non-ionic species and so are useful in solid dosage forms. Furthermore, because their solubility often is a function of pH, selective dissolution in one or another part of the digestive tract is possible and this capability can be manipulated as one aspect of delayed and sustained release behaviours. Also, because the salt- forming molecule can be in equilibrium with a neutral form, passage through biological membranes can be adjusted.
• pharmaceutically acceptable salts are obtained by reacting a compound described herein with an acid.
• the compound described herein i.e. free base form
• the compound described herein is basic and is reacted with an organic acid or an inorganic acid.
• Inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and metaphosphoric acid.
• Organic acids include, but are not limited to, l-hydroxy-2-naphthoic acid; 2,2-dichloroacetic acid; 2 -hydroxy ethanesulfonic acid; 2- oxoglutaric acid; 4-acetamidobenzoic acid; 4-aminosalicylic acid; acetic acid; adipic acid;
• a compound described herein is prepared as a chloride salt, sulfate salt, bromide salt, mesylate salt, maleate salt, citrate salt or phosphate salt. In some embodiments, a compound described herein is prepared as a hydrochloride salt.
• pharmaceutically acceptable salts are obtained by reacting a compound described herein with a base.
• the compound described herein is acidic and is reacted with a base.
• an acidic proton of the compound described herein is replaced by a metal ion, e.g., lithium, sodium, potassium, magnesium, calcium, or an aluminum ion.
• compounds described herein coordinate with an organic base, such as, but not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, meglumine, N-methylglucamine, dicyclohexylamine,
• compounds described herein form salts with amino acids such as, but not limited to, arginine, lysine, and the like.
• Acceptable inorganic bases used to form salts with compounds that include an acidic proton include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydroxide, lithium hydroxide, and the like.
• the compounds provided herein are prepared as a sodium salt, calcium salt, potassium salt, magnesium salt, meglumine salt, N-methylglucamine salt or ammonium salt.
• the compounds provided herein are prepared as a sodium salt.
• solvates contain either stoichiometric or non- stoichiometric amounts of a solvent, and are formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of compounds described herein are conveniently prepared or formed during the processes described herein. In addition, the compounds provided herein optionally exist in unsolvated as well as solvated forms.
• N-oxides if appropriate
• crystalline forms also known as polymorphs
• pharmaceutically acceptable salts of compounds described herein as well as active metabolites of these compounds having the same type of activity.
• sites on the organic radicals (e.g. alkyl groups, aromatic rings) of compounds described herein are susceptible to various metabolic reactions. Incorporation of appropriate substituents on the organic radicals will reduce, minimize or eliminate this metabolic pathway.
• the appropriate substituent to decrease or eliminate the susceptibility of the aromatic ring to metabolic reactions is, by way of example only, a halogen, deuterium, an alkyl group, a haloalkyl group, or a deuteroalkyl group.
• Compounds described herein include isotopically-labeled compounds, which are identical to those recited in the various formulae and structures presented herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
• isotopes that can be incorporated into the present compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine and chlorine, such as, for example, 2 H, 3 H, 13 C, 14 C, 15 N, 18 0, 17 0, 35 S, 18 F, 36 C1.
• isotopically-labeled compounds described herein for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays.
• substitution with isotopes such as deuterium affords certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements.
• the compounds described herein possess one or more stereocenters and each stereocenter exists independently in either the R or S configuration.
• the compounds presented herein include all diastereomeric, enantiomeric, atropisomers, and epimeric forms as well as the appropriate mixtures thereof.
• the compounds and methods provided herein include all cis, trans, syn, anti,
• E
• Z
• isomers as well as the appropriate mixtures thereof.
• stereoisomers are obtained, if desired, by methods such as, stereoselective synthesis and/or the separation of stereoisomers by chiral chromatographic columns.
• compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds/salts, separating the diastereomers and recovering the optically pure enantiomers.
• resolution of enantiomers is carried out using covalent diastereomeric derivatives of the compounds described herein.
• diastereomers are separated by separation/resolution techniques based upon differences in solubility.
• separation of steroisomers is performed by chromatography or by the forming diastereomeric salts and separation by recrystallization, or chromatography, or any combination thereof.
• stereoisomers are obtained by stereoselective synthesis.
• compounds described herein are prepared as prodrugs.
• a "prodrug” refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they are easier to administer than the parent drug. They are, for instance, bioavailable by oral administration whereas the parent is not. Further or
• the prodrug also has improved solubility in pharmaceutical compositions over the parent drug.
• the design of a prodrug increases the effective water solubility.
• a prodrug is a compound described herein, which is administered as an ester (the "prodrug") but then is metabolically hydrolyzed to provide the active entity.
• a further example of a prodrug is a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety.
• a prodrug upon in vivo administration, a prodrug is chemically converted to the biologically,
• a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound.
• Prodrugs of the compounds described herein include, but are not limited to, esters, ethers, carbonates, thiocarbonates, N-acyl derivatives, N-acyloxyalkyl derivatives, quaternary derivatives of tertiary amines, N-Mannich bases, Schiff bases, amino acid conjugates, phosphate esters, and sulfonate esters. See for example Design of Prodrugs, Bundgaard, A. Ed., Elseview, 1985 and Method in Enzymology, Widder, K. et al, Ed.; Academic, 1985, vol. 42, p. 309-396; Bundgaard, H.
• a hydroxyl group in the compounds disclosed herein is used to form a prodrug, wherein the hydroxyl group is incorporated into an acyloxyalkyl ester, alkoxycarbonyloxyalkyl ester, alkyl ester, aryl ester, phosphate ester, sugar ester, ether, and the like.
• a hydroxyl group in the compounds disclosed herein is a prodrug wherein the hydroxyl is then metabolized in vivo to provide a carboxylic acid group.
• a carboxyl group is used to provide an ester or amide (i.e. the prodrug), which is then metabolized in vivo to provide a carboxylic acid group.
• compounds described herein are prepared as alkyl ester prodrugs. [00166] Prodrug forms of the herein described compounds, wherein the prodrug is metabolized in vivo to produce a compound described herein as set forth herein are included within the scope of the claims. In some cases, some of the herein-described compounds is a prodrug for another derivative or active compound.
• the compounds described herein are metabolized upon administration to an organism in need to produce a metabolite that is then used to produce a desired effect, including a desired therapeutic effect.
• a "metabolite” of a compound disclosed herein is a derivative of that compound that is formed when the compound is metabolized.
• active metabolite refers to a biologically active derivative of a compound that is formed when the compound is metabolized.
• metabolism refers to the sum of the processes (including, but not limited to, hydrolysis reactions and reactions catalyzed by enzymes) by which a particular substance is changed by an organism. Thus, enzymes may produce specific structural alterations to a compound.
• cytochrome P450 catalyzes a variety of oxidative and reductive reactions while uridine diphosphate glucuronyltransferases catalyze the transfer of an activated glucuronic-acid molecule to aromatic alcohols, aliphatic alcohols, carboxylic acids, amines and free sulphydryl groups.
• Metabolites of the compounds disclosed herein are optionally identified either by administration of compounds to a host and analysis of tissue samples from the host, or by incubation of compounds with hepatic cells in vitro and analysis of the resulting compounds.
• Standard techniques are optionally used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients. Standard techniques are optionally used for recombinant DNA,
• oligonucleotide synthesis and tissue culture and transformation (e.g., electroporation, lipofection). Reactions and purification techniques are performed using documented
• the compounds described herein are formulated into
• compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that are used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
• a summary of pharmaceutical compositions described herein is found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975;
• the compounds described herein are administered either alone or in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition.
• Administration of the compounds and compositions described herein can be effected by any method that enables delivery of the compounds to the site of action. These methods include, though are not limited to delivery via enteral routes (including oral, gastric or duodenal feeding tube, rectal suppository and rectal enema), parenteral routes
• injection or infusion including intraarterial, intracardiac, intradermal, intraduodenal,
• compounds described herein can be administered locally to the area in need of treatment, by for example, local infusion during surgery, topical application such as creams or ointments, injection, catheter, or implant.
• the administration can also be by direct injection at the site of a diseased tissue or organ.
• compositions suitable for oral administration are presented as discrete units such as capsules, cachets or tablets each containing a
• the active ingredient is presented as a bolus, electuary or paste.
• compositions which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
• the tablets are coated or scored and are formulated so as to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration.
• the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
• the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In some embodiments, stabilizers are added. Dragee cores are provided with suitable coatings.
• concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
• Dyestuffs or pigments may be added to the tablets or Dragee coatings for identification or to characterize different combinations of active compound doses.
• compositions are formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
• Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
• the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
• compositions may be presented in unit-dose or multi- dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use.
• sterile liquid carrier for example, saline or sterile pyrogen-free water
• Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
• compositions for parenteral administration include aqueous and nonaqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
• Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
• Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
• the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
• compositions may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
• the compounds may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
• compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner.
• Such compositions may comprise the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.
• compositions may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
• compositions may be administered topically, that is by non-systemic administration.
• non-systemic administration includes the application of a compound of the present invention externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.
• systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
• compositions suitable for topical administration include liquid or semi- liquid preparations suitable for penetration through the skin to the site of inflammation such as gels, liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
• the active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the formulation.
• compositions for administration by inhalation are conveniently delivered from an insufflator, nebulizer pressurized packs or other convenient means of delivering an aerosol spray.
• Pressurized packs may comprise a suitable propellant such as dichlorodif uoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
• the dosage unit may be determined by providing a valve to deliver a metered amount.
• pharmaceutical preparations may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch.
• the powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
• compositions described herein may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
• the compounds described herein, or a pharmaceutically acceptable salt thereof are used in the preparation of medicaments for the treatment of diseases or conditions in a mammal that would benefit from inhibition or reduction of autotaxin activity.
• Methods for treating any of the diseases or conditions described herein in a mammal in need of such treatment involves administration of pharmaceutical compositions that include at least one compound described herein or a pharmaceutically acceptable salt, active metabolite, prodrug, or pharmaceutically acceptable solvate thereof, in therapeutically effective amounts to said mammal.
• compositions containing the compound(s) described herein are administered for prophylactic and/or therapeutic treatments.
• the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest at least one of the symptoms of the disease or condition. Amounts effective for this use depend on the severity and course of the disease or condition, previous therapy, the patient's health status, weight, and response to the drugs, and the judgment of the treating physician.
• Therapeutically effective amounts are optionally determined by methods including, but not limited to, a dose escalation and/or dose ranging clinical trial.
• compositions containing the compounds described herein are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder or condition. Such an amount is defined to be a "prophylactically effective amount or dose.”
• prophylactically effective amount or dose the precise amounts also depend on the patient's state of health, weight, and the like. When used in patients, effective amounts for this use will depend on the severity and course of the disease, disorder or condition, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician.
• prophylactic treatments include administering to a mammal, who previously experienced at least one symptom of the disease being treated and is currently in remission, a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt thereof, in order to prevent a return of the symptoms of the disease or condition.
• the administration of the compounds are administered chronically, that is, for an extended period of time, including throughout the duration of the patient's life in order to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition.
• the dose of drug being administered is temporarily reduced or temporarily suspended for a certain length of time (i.e., a "drug holiday").
• the length of the drug holiday is between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, or more than 28 days.
• the dose reduction during a drug holiday is, by way of example only, by 10%- 100%, including by way of example only 10%>, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%.
• a maintenance dose is administered if necessary. Subsequently, in specific embodiments, the dosage or the frequency of administration, or both, is reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained. In certain embodiments, however, the patient requires intermittent treatment on a long-term basis upon any recurrence of symptoms.
• the amount of a given agent that corresponds to such an amount varies depending upon factors such as the particular compound, disease condition and its severity, the identity (e.g., weight, sex) of the subject or host in need of treatment, but nevertheless is determined according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated.
• doses employed for adult human treatment are typically in the range of 0.01 mg-5000 mg per day. In one aspect, doses employed for adult human treatment are from about 1 mg to about 1000 mg per day. In one embodiment, the desired dose is conveniently presented in a single dose or in divided doses administered simultaneously or at appropriate intervals, for example as two, three, four or more sub-doses per day.
• the daily dosages appropriate for the compound described herein, or a pharmaceutically acceptable salt thereof are from about 0.01 to about 50 mg/kg per body weight. In some embodiments, the daily dosage or the amount of active in the dosage form are lower or higher than the ranges indicated herein, based on a number of variables in regard to an individual treatment regime. In various embodiments, the daily and unit dosages are altered depending on a number of variables including, but not limited to, the activity of the compound used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.
• Toxicity and therapeutic efficacy of such therapeutic regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LD 5 o and the ED 5 o.
• the dose ratio between the toxic and therapeutic effects is the therapeutic index and it is expressed as the ratio between LD 5 o and ED50.
• the data obtained from cell culture assays and animal studies are used in formulating the therapeutically effective daily dosage range and/or the therapeutically effective unit dosage amount for use in mammals, including humans.
• the daily dosage amount of the compounds described herein lies within a range of circulating concentrations that include the ED 5 o with minimal toxicity.
• the daily dosage range and/or the unit dosage amount varies within this range depending upon the dosage form employed and the route of administration utilized.
• the effective amount of the compound described herein, or a pharmaceutically acceptable salt thereof is: (a) systemically administered to the mammal; and/or (b) administered orally to the mammal; and/or (c) intravenously administered to the mammal; and/or (d) administered by injection to the mammal; and/or (e) administered topically to the mammal; and/or (f) administered non- systemically or locally to the mammal.
• any of the aforementioned aspects are further embodiments comprising single administrations of the effective amount of the compound, including further embodiments in which (i) the compound is administered once a day; or (ii) the compound is administered to the mammal multiple times over the span of one day.
• any of the aforementioned aspects are further embodiments comprising multiple administrations of the effective amount of the compound, including further embodiments in which (i) the compound is administered continuously or intermittently: as in a single dose; (ii) the time between multiple administrations is every 6 hours; (iii) the compound is administered to the mammal every 8 hours; (iv) the compound is administered to the mammal every 12 hours; (v) the compound is administered to the mammal every 24 hours.
• the compound is administered continuously or intermittently: as in a single dose; (ii) the time between multiple administrations is every 6 hours; (iii) the compound is administered to the mammal every 8 hours; (iv) the compound is administered to the mammal every 12 hours; (v) the compound is administered to the mammal every 24 hours.
• the method comprises a drug holiday, wherein the administration of the compound is temporarily suspended or the dose of the compound being administered is temporarily reduced; at the end of the drug holiday, dosing of the compound is resumed.
• the length of the drug holiday varies from 2 days to 1 year.
• the pharmaceutical composition further comprises one or more anti-diabetic agents.
• the pharmaceutical composition further comprises one or more agents used to treat cardiovascular disease.
• the cardiovascular agent is selected from the group consisting of: an angiotensin-converting enzyme (ACE ) inhibitor, angiotensin II receptor blocker (ARB), beta-blocker, diuretic, calcium channel blocker, inhibitor of renin-angiotensin system (RAS), blood-thinning medication, a statin, and a fibrate, and any combination thereof
• the therapeutic effectiveness of one of the compounds described herein is enhanced by administration of an adjuvant (i.e., by itself the adjuvant has minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced).
• an adjuvant i.e., by itself the adjuvant has minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced.
• the benefit experienced by a patient is increased by administering one of the compounds described herein with another agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
• a compound described herein, or a pharmaceutically acceptable salt thereof is co-administered with a second therapeutic agent, wherein the compound described herein, or a pharmaceutically acceptable salt thereof, and the second therapeutic agent modulate different aspects of the disease, disorder or condition being treated, thereby providing a greater overall benefit than administration of either therapeutic agent alone.
• the overall benefit experienced by the patient is simply be additive of the two therapeutic agents or the patient experiences a synergistic benefit.
• different therapeutically-effective dosages of the compounds disclosed herein will be utilized in formulating pharmaceutical composition and/or in treatment regimens when the compounds disclosed herein are administered in combination with one or more additional agent, such as an additional therapeutically effective drug, an adjuvant or the like.
• additional agent such as an additional therapeutically effective drug, an adjuvant or the like.
• Therapeutically-effective dosages of drugs and other agents for use in combination treatment regimens is optionally determined by means similar to those set forth hereinabove for the actives themselves.
• the methods of prevention/treatment described herein encompasses the use of metronomic dosing, i.e., providing more frequent, lower doses in order to minimize toxic side effects.
• a combination treatment regimen i.e., providing more frequent, lower doses in order to minimize toxic side effects.
• treatment regimens in which administration of a compound described herein, or a pharmaceutically acceptable salt thereof, is initiated prior to, during, or after treatment with a second agent described herein, and continues until any time during treatment with the second agent or after termination of treatment with the second agent. It also includes treatments in which a compound described herein, or a pharmaceutically acceptable salt thereof, and the second agent being used in combination are administered simultaneously or at different times and/or at decreasing or increasing intervals during the treatment period. Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical management of the patient.
• the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought is modified in accordance with a variety of factors (e.g. the disease, disorder or condition from which the subject suffers; the age, weight, sex, diet, and medical condition of the subject).
• factors e.g. the disease, disorder or condition from which the subject suffers; the age, weight, sex, diet, and medical condition of the subject.
• the dosage regimen actually employed varies and, in some embodiments, deviates from the dosage regimens set forth herein.
• the compounds vary depending on the type of co-drug employed, on the specific drug employed, on the disease or condition being treated and so forth.
• the compound provided herein when coadministered with one or more other therapeutic agents, is administered either simultaneously with the one or more other therapeutic agents, or sequentially.
• the multiple therapeutic agents are administered in any order or even simultaneously. If administration is simultaneous, the multiple therapeutic agents are, by way of example only, provided in a single, unified form, or in multiple forms (e.g., as a single pill or as two separate pills).
• the compounds described herein, or a pharmaceutically acceptable salt thereof, as well as combination therapies, are administered before, during or after the occurrence of a disease or condition, and the timing of administering the composition containing a compound varies.
• the compounds described herein are used as a prophylactic and are administered continuously to subjects with a propensity to develop conditions or diseases in order to prevent the occurrence of the disease or condition.
• the compounds and compositions are administered to a subject during or as soon as possible after the onset of the symptoms.
• a compound described herein is administered as soon as is practicable after the onset of a disease or condition is detected or suspected, and for a length of time necessary for the treatment of the disease.
• the length required for treatment varies, and the treatment length is adjusted to suit the specific needs of each subject.
• a compound described herein or a formulation containing the compound is administered for at least 2 weeks, about 1 month to about 5 years.
• kits for decreasing blood glucose levels in an individual with a metabolic disorder in need thereof comprising administering to said individual an autotaxin inhibitor.
• kits include a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) including one of the separate elements to be used in a method described herein.
• Suitable containers include, for example, bottles, vials, syringes, and test tubes.
• the containers can be formed from a variety of materials such as glass or plastic.
• the articles of manufacture provided herein contain packaging materials.
• packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment.
• a wide array of formulations of the compounds and compositions provided herein are contemplated as are a variety of treatments for any disorder that benefit by inhibition of ATX, or in which ATX is a mediator or contributor to the symptoms or cause.
• the container(s) optionally have a sterile access port (for example the container is an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
• a sterile access port for example the container is an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle.
• kits optionally comprising a compound with an identifying description or label or instructions relating to its use in the methods described herein.
• a kit will typically include one or more additional containers, each with one or more of various materials (such as reagents, optionally in concentrated form, and/or devices) desirable from a commercial and user standpoint for use of a compound described herein.
• materials include, but not limited to, buffers, diluents, filters, needles, syringes; carrier, package, container, vial and/or tube labels listing contents and/or instructions for use, and package inserts with instructions for use.
• a set of instructions will also typically be included.
• a label is on or associated with the container.
• a label can be on a container when letters, numbers or other characters forming the label are attached, molded or etched into the container itself; a label can be associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert.
• a label can be used to indicate that the contents are to be used for a specific therapeutic application. The label can also indicate directions for use of the contents, such as in the methods described herein.
• a pharmaceutical composition comprising the ATX inhibitor is presented in a pack or dispenser device which can contain one or more unit dosage forms.
• the pack can for example contain metal or plastic foil, such as a blister pack.
• the pack or dispenser device can be accompanied by instructions for administration.
• the pack or dispenser can also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration.
• a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration.
• Such notice for example, can be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert.
• Compositions containing a compound provided herein formulated in a compatible pharmaceutical carrier can also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
• Step 1 Sthesis of fS)-2,3,4,9-tetrahvdro-lH-pyrido[3,4-blindole-3-carboxylic acid (1):
• Step 2 Synthesis of fS)-2-ftert-butoxycarbonyl)-2,3i4,9-tetrahvdro-lH-pyrido[3.,4-blin(iole- 3-carboxylic acid (2):
• Step 3 Synthesis of fS)-2-ftert-butoxycarbonyl)-9-f4-fluorobenzyl)-2,3i4,9-tetrahvdro-lH- pyrido[3.,4-blindole-3-carboxylic acid (3):
• Step 6 Synthesis of tert-butyl (S)-3-(6-(4-fluorobenzyl)-l,3-dioxo-5,6,ll,lla-tetrahvdro-lH- imidazo [ 1 5 ' : 1 ,61 pyrido [3,4-bl indol-2(3H)-yl)propanoate (6) :
• the crude material was purified through a silica gel column with 10 % EtOAc/CH 2 Cl 2 . The fractions concentrated under reduce pressure to provide a solid. The solid was washed with 10 % CH 2 C1 2 /Hexane to afford the ester 6 (25.9 g, 84 %).
• the foam was dissolved in isopropyl acetate (75 mL) and then ether (75 mL) was added. Pentane (10 mL) was added to the solution and sonicated until a precipitate formed. Pentane (100 mL) was added. The mixture stirred at RT for 1.5 hr.
• Step 8 Synthesis of (S)-3-(6-(4-fluorobenzyl)-l,3-dioxo-5. l 6. l ll. l lla-tetrahvdro-lH-imidazo [l ⁇ 5':l,61pyrido[3,4-blindol-2(3H)-yl)propanoic acid sodium salt (Compound A sodium salt):
• Step 1 Synthesis of l-f2-amino-4-chloro-3-fluorophenyl)-2-chloroethan-l-one (2):
• reaction mixture was then cooled to 0 °C, added aqueous 3N HCI solution (100 mL) and raised the temperature to reflux and stirred for 3 h.
• aqueous 3N HCI solution 100 mL
• the reaction mixture was cooled RT, diluted with water (50 mL) and extracted with CH 2 CI 2 (2 x 150 mL).
• the combined organic extracts were dried over Na 2 S0 4 , filtered and concentrated under reduced pressure to obtain the crude.
• the crude was purified by triturating with n-pentane to afford compound 2 (4.5 g, 33%) as an off- white solid.
• Step 3 Synthesis of 4-bromo-l-ethyl-lH-pyrazole (4):
• Step 4 Synthesis of 6-chloro-2-cyclopropyl-l-fl-ethyl-lH-pyrazol-4-yl)-7-fluoro-lH-indole
• reaction mixture was heated to 90 °C and stirred for 2 h.
• the reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with hexane (450 mL) and stirred at RT for 15 min.
• the resultant solution was filtered through celite and washed with hexane (100 mL).
• the filtrate was washed water (250 mL) dried over Na 2 S0 4 , filtered and concentrated under reduced pressure to obtain the crude.
• the crude was purified through silica gel column chromatography using 3-4% EtOAc/Hexanes to afford compound A3 (15 g, 88%) as pale yellow solid.
• Step 8 Synthesis of ethyl 3-(Y6-chloro-2-cvclopropyl-l-Q-ethyl-lH-pyrazol-4-yl)-7-fluoro- lH-indol-3-yl)thio)-2-fluorobenzoate (7):
• Step 9 Synthesis of 3-ff6-chloro-2-cyclopropyl-l-fl-ethyl-lH-pyrazol-4-yl)-7-fluoro-lH- indol-3-yl)thio)-2-fluorobenzoic acid sodium salt (8):
• Step 1 Synthesis of 6-chloro-l-(l-ethyl-lH-pyrazol-4-yl)-7-fluoro-lH-indole (9):
• reaction mixture was cooled to RT, diluted with hexane (10 mL) and filtered through a short pad of celite. The filtrate was washed with water (2x10 mL), dried over Na 2 S0 4 , filtered and concentrated under reduced pressure to obtain the crude. The crude was purified (silica gel chromatography; 8-10% EtOAc/Hexanes) to afford compound 9 (224 mg, 36%) as a light brown thick liquid.
• Step 2 Synthesis of ethyl 3-((6-chloro-l-a-ethyl-lH-pyrazol-4-yl)-7-fluoro-lH-indol-3- yl)thio)-2-fluorobenzoate (10):
• Step 3 Synthesis of ethyl 3-((2-bromo-6-chloro-l-(l-ethyl-lH-pyrazol-4-yl)-7-fluoro-lH- indol-3-yl)thio)-2-fluorobenzoate (11 :
• Step 4 Synthesis of ethyl 3-((6-chloro-2-cyclopropyl-l-(l-ethyl-lH-pyrazol-4-yl)-7-fluoro- lH-indol-3-yl)thio)-2-fluorobenzoate (7):
• Step 2 Synthesis of 6-chloro-7-fluoro-l-fl-propyl-lH-pyrazol-4-yl)-lH-indole (3):
• reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with EtOAc (30 mL), filtered and the filtrate was concentrated under reduced pressure to obtain the crude. This was purified by silica gel column chromatography using 8-10% EtOAc/ Hexanes to afford compound 4 (1.3 g, 72%) as brown liquid.
• Step 3 Synthesis of ethyl 3-((6-chloro-7-fluoro-l-(l-propyl-lH-pyrazol-4-yl)-lH-indol-3- yl)thio)-2-fluorobenzoate (6):
• Step 4 Synthesis of ethyl 3-((2,6-dichloro-7-fluoro-l-(l-propyl-lH-pyrazol-4-yl)-lH-indol- 3-yl)thio)-2-fluorobenzoate (7):
• reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with CH 2 CI 2 (2 x 20 mL). The combined organic extracts were washed with brine (15 mL), dried over Na 2 S0 4 , filtered and concentrated under reduced pressure to obtain the crude.
• Step 5 Synthesis of 3-ff2,6-dichloro-7-fluoro-l-fl-propyl-lH-pyrazol-4-yl)-lH-indol-3- yl)thio)-2-fluorobenzoic acid (Compound C):
• Step 1 Synthesis of l-f2-amino-4-chloro-3-fluorophenyl)-2-chloroethan-l-one (2):
• reaction mixture was then cooled to 0 °C, added aqueous 3N HC1 solution (100 mL) and raised the temperature to reflux and stirred for 3 h.
• TLC aqueous 3N HC1 solution
• the reaction mixture was cooled RT, diluted with water (50 mL) and extracted with CH 2 CI 2 (2 x 150 mL).
• the combined organic extracts were dried over Na 2 S0 4 , filtered and concentrated under reduced pressure to obtain the crude.
• the crude was purified by triturating with n-pentane to afford compound 2 (4.5 g, 33%) as an off- white solid.
• Step 3 Synthesis of 6-chloro-2-cvclopropyl-l-fl-ethyl-lH-pyrazol-4-yl)-7-fluoro-lH-indole
• Step 6 Synthesis of methyl 6-(Y6-chloro-2-cvclopropyl-l-( l-ethyl-lH-pyrazol-4-yl)-7-fluoro- lH-indol-3-yl)thio)picolinate (9):
• Step 7 Synthesis of 6-((6-chloro-2-cvclopropyl-l-( l-ethyl-lH-pyrazol-4-yl)-7-fluoro-lH- indol-3-yl)thio)picolinic acid sodium salt (Compound D sodium salt) :
• Step 2 ethyl 3-((6-chloro-7-fluoro-2-methyl-lH-indol-3-yl) thio)-2-fluorobenzoate (4):
• Step 3 ethyl 3-( -(2-(tert-butoxy)-2-oxoethyl)-6-chloro-7-fluoro-2-methyl-lH-indol-3-yl) thio)-2-fluorobenzoate (5):
• Step 4 2-( ⁇ -chloro-3-(T3-(ethoxycarbonyl)-2-fluorophenyl) thio)-7-fluoro-2-methyl-lH- indol-l-yl) acetic acid (6):
• Step 5 ethyl 3-ff6-chloro-7-fluoro-l-f2-f3-hvdroxy-3-ftrifluoromethyl)pyrrolidin-l-yl)-2- oxoethyl)-2-methyl-lH-indol-3-yl)thio)-2-fluorobenzoate racemic 8
• Step 6 Resolution: ethyl 3-((6-chloro-7-fluoro-l-(2-(3-hvdroxy-3-(trifluoromethyl) pyrrolidin-l-yl)-2-oxoethyl)-2-methyl-lH-indol-3-yl)thio)-2-fluorobenzoate
• Enantiomer 8A
• Racemic compound 8 (1 lg) was purified by chiral chromatography using Chiralpak- AD-H column eluting with 90: 10 of Phase A (0.1% TFA in n-hexane): Phase B (EtOH:MeOH 50:50). The first eluted compound was collected to give compound 8A (4.3g).
• HPLC 98.6%; (column: Acquity BEH C-18 (50 x 2.1 mm, 1.7 ⁇ ); RT 3.10 min.
• LC-MS 577.5 (M + +l)
• Step 7 3-ff6-chloro-7-fluoro-l-f2-f3-hydroxy-3-ftrifluoromethyl)pyrrolidin-l-yl)-2- oxoethyl)-2-methyl-lH-indol-3-yl)thio)-2-fluorobenzoate (Compound E)
• ATX activity is assayed in concentrated conditioned media from Hep3B human hepatocellular carcinoma cells by measuring the amount of choline released from the substrate, lysophosphatidylcholine (LPC) as it is cleaved to LPA.
• LPC lysophosphatidylcholine
• Conditioned media is collected from confluent Hep3B cells and concentrated 20-fold using Centriprep-30 filter devices (Millipore).
• lyso-PLD buffer 100 mM Tris pH 9, 500 mM NaCl, 5 mM MgCl 2 , 5 mM CaCl 2 , 0.05% Triton X-100 in the presence or absence of
• Example 7 Effects of autotaxin inhibitors on glucose tolerance in mice fed a high fat diet.
• mice C57B16/J male mice were fed a normal diet until 9-10 weeks of age. Mice were then fed either a normal diet (ND) or high-fat diet (HFD) (20% protein, 35% carbohydrate, 45% fat; Harlan Laboratories) for 8-10 weeks. For determination of blood glucose, mice were
• test compound administered test compound orally in 0.5% methocel once or twice daily for several days prior to the glucose challenge.
• Compounds were administered as a sodium salt.
• GTT glucose tolerance test mice were fasted for 6-8 hours and a last dose of test compound
• Compound A (30 mg/kg) or Compound D (30 mg/kg) twice daily for two days prior to sampling and once on the day of sampling decrease baseline glucose and total blood glucose AUC.
• Compound B (30 mg/kg) or Compound E (30 mg/kg) once daily for 5 days prior to sampling decrease baseline glucose.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Diabetes (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Cardiology (AREA)
• Child & Adolescent Psychology (AREA)
• Heart & Thoracic Surgery (AREA)
• Gastroenterology & Hepatology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (1)

Family

ID=53267810

Family Applications (1)

Country Status (4)

Cited By (6)

Families Citing this family (13)

Citations (4)

Family Cites Families (42)

• 2014
  • 2014-08-18 US US14/462,459 patent/US9051320B1/en not_active Expired - Fee Related
• 2015
  • 2015-08-17 WO PCT/US2015/045518 patent/WO2016028686A1/en not_active Ceased
  • 2015-08-17 JP JP2017508482A patent/JP6817190B2/ja active Active
  • 2015-08-17 EP EP15833802.0A patent/EP3183005A4/en not_active Withdrawn

Patent Citations (4)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events